Future Treatments for Parkinson's Disease: Surfing the PD Pipeline

REFERENCES

• Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190–9.
   PubMed Web of Science ®Google Scholar
• Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord. 2009;15:406–13.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Schwarzschild MA. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging. 2005;22:471–82.
   PubMed Web of Science ®Google Scholar
• Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998;43:507–13.
   PubMed Web of Science ®Google Scholar
• Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000;162:321–7.
   PubMed Web of Science ®Google Scholar
• Grondin R, Bédard PJ, Hadj Tahar A, Grégoire L, Mori A, Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology. 1999;52:1673–7.
   PubMed Web of Science ®Google Scholar
• Hodgson RA, Bedard PJ, Varty GB, Kazdoba TM, Di Paolo T, Grzelak ME, Pond AJ, Hadjtahar A, Belanger N, Gregoire L, Dare A, Neustadt BR, Stamford AW, Hunter JC. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Exp Neurol. 2010;225:384–90.
   PubMed Web of Science ®Google Scholar
• Prediger RD. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis. 2010;20 Suppl 1:S205–20.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem. 2002;80:262–70.
   PubMed Web of Science ®Google Scholar
• Kalda A, Yu L, Oztas E, Chen JF. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J Neurol Sci. 2006;248:9–15.
   PubMed Web of Science ®Google Scholar
• Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology. 2003;61:293–6.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hubble JP, Truong DD; Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003;61:297–303.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM; 6002-US-005 Study Group. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63:295–302.
   PubMed Web of Science ®Google Scholar
• Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70:2233–40.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM; Istradefylline 6002-US-013 Study Group. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord. 2008;23:2177–85.
   PubMed Web of Science ®Google Scholar
• Guttman M. Efficacy of istradefylline in Parkinson's disease patients treated with levodopa with motor fluctuations. Mov Disord. 2006;21 Suppl 15:S585.
   PubMed Web of Science ®Google Scholar
• FDA Issues Not Approvable Letter for Istradefylline. http:// www.drugs.com/nda/kw_6002_080228.html, accessed 2/24/11.
   Google Scholar
• Hauser RA, Auinger P; Parkinson Study Group. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord. 2011;26:813–8.
   Google Scholar
• Kyowa Pharmaceutical, Inc. Kyowa Pharmaceutical suspends development of istradefylline in North America [Internet]. 2008 [cited 2011 Feb 24]. http://www.michaeljfox.org/ newsEvents_parkinsonsInTheNews_article.cfm?ID=353
   Google Scholar
• Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M; Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord. 2010;25:1437–43.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Greeley DR, Zweig RM, Wojcieszek J, Mori A, Sussman NM; 6002-US-051 Study Group. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord. 2010;16:16–20.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10:221–9.
   PubMed Web of Science ®Google Scholar
• Black KJ, Campbell MC, Dickerson W, Creech ML, Koller JM, Chung C, Bandak SI. A randomized, double-blind, placebo-controlled crossover trial of the adenosine 2a antagonist SYN115 in Parkinson Disease. Neurology. 2010;74 Suppl 2:A317.
   Google Scholar
• Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA, Chase TN. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol. 2003;184:285–94.
   PubMed Web of Science ®Google Scholar
• Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother. 2007;8:657–864.
   PubMed Web of Science ®Google Scholar
• Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother. 2006;6:1403–11.
   PubMedGoogle Scholar
• Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr Med Res Opin. 2011;27:907–19.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernäs H, Nyström C, Aquilonius SM. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003;26: 156–63.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H. Duodenal levodopa infusion monotherapy vs. oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216–23.
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, Pezzoli G. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord. 2007;22:1145–9.
   PubMed Web of Science ®Google Scholar
• Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R, Oertel W, Odin P. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol. 2008;31:151–66.
   PubMed Web of Science ®Google Scholar
• Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease—long-term experience. Acta Neurol Scand. 2001;104:343–8.
   PubMed Web of Science ®Google Scholar
• Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24:1468–74.
   PubMed Web of Science ®Google Scholar
• Devos D; French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord. 2009;24:993–1000.
   PubMed Web of Science ®Google Scholar
• Espay AJ, Chatamra K, Fernandez HH, Standaert DG, Hauser RA, Benesh J, Caras SD, Pritchett YL, Lenz RA. Interim results of motor-symptom endpoints of an ongoing, open-label study of levodopa-carbidopa intestinal gel in Parkinson's disease patients with severe motor fluctuations. Mov Disord. 2011;26 Suppl 2:S126.
   Google Scholar
• Standaert DG, Espay AJ, Fernandez HH, Benesh J, Lenz RA, Pritchett YL, Hass S, Chatamra K. Interim results of quality-of-life endpoints of an open-label study of levodopa-carbidopa intestinal gel in Parkinson's disease patients with severe motor fluctuations. Mov Disord. 2011;26 Suppl 2:S141–2.
   Google Scholar
• Vanagunas A, Chatamra K, Standaert DG, Espay AJ, Fernandez HH, Benesh J, Caras SD, Robieson WZ, Lenz RA Interim results of safety endpoints of an open-label, long-term safety study of levodopa-carbidopa intestinal gel in Parkinson's disease patients with severe motor fluctuations. Mov Disord. 2011;26 Suppl 2:S144.
   Google Scholar
• Olanow CW, Chatamra K, Benesh J, Pritchett YL, Lenz RA. Design of a randomized, double-blind, double-dummy, placebo-controlled study of levodopa-carbidopa intestinal gel in patients currently receiving optimized treatment for advanced Parkinson's disease. Mov Disord. 2011;26 Suppl 2:S137.
   Google Scholar
• Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, Molho ES, Factor SA. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23:75–81.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord. 2004;19:1409–13.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O'Connell MJ, Modi NB, Yao HM, Kell SH, Gupta SK. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord. 2011 Jul 13. [Epub ahead of print]
   Google Scholar
• Hauser RA, Nausieda P, Ondo W, Espay AJ, Hsu A, O'Connell M, Kell S, Gupta S. Double-blind, controlled trial of IPX066, a novel carbidopa-levodopa extended-release formulation, in advanced Parkinson's disease (ADVANCE-PD trial). Movement Disorder Society Meeting 2011, late breaking abstract LB9.
   Google Scholar
• Pahwa R, Ellenbogen A, Jankovic J, Hauser R, Fahn S, Clinical Team at Impax Pharmaceuticals. Efficacy and safety of IPX066, a new carbidopa-levodopa (CD-LD) extended-release formulation, in LD-naïve early Parkinson's disease (APEX-PD trial). Mov Disord. 2011;26 Suppl 2:S137.
   Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677–87.
   PubMed Web of Science ®Google Scholar
• XenoPort, Inc. XenoPort announces positive results of a phase 1 clinical trial of XP21279 [Internet]. 2008 [cited 2011 Apr 15]. Available from: http://www.drugs.com/clinical_trials/xenoport-announces-positive-results-phase-1-clinical-trial-xp21279-3559.html
   Google Scholar
• LeWitt P, Ellenbogen A, Chen D, Lal R, McGuire K, Zomorodi K, Lou W, Huff FJ. Actively-transported levodopa prodrug XP21279: a study in Parkinson's disease subjects experiencing motor fluctuations. Mov Disord. 2011;26 Suppl 2:S282.
   Google Scholar
• Heldman E, Kushnir M. Alleviating late motor complications of PD by a continuous dopaminergic treatment with transdermal delivery of levodopa pro-drug [Internet]. 2006 [cited 2011 Apr 16]. Available from: www.michaeljfox.org/research_MJFFfundingPortfolio_searchableAwardedGrants_3.cfm?ID=225&#Update_1.
   Google Scholar
• Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67 Suppl 2:S18–23.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, Bonuccelli U, Van Dijk A, Cattaneo C, Sala P, Fariello RG; Safinamide Parkinson's Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63:746–8.
   PubMed Web of Science ®Google Scholar
• Meshram CM, Bhatt M, Chirileanu, Stanzione P, Lucini V, Rossetti SM, Anand R. The Study 016 Investigators Safinamide as add-on to levodopa improves motor function without worsening dyskinesia in patients with mid-late Parkinson's disease. Mov Disord. 2010;25 Suppl 2:S302.
   Google Scholar
• Gregoire L, Roach A, Di Paola T. Safinamide reduces levodopa-induced dyskinesia in MPTP-lesioned primates while prolonging anti-parkinsonian efficacy. Mov Disord. 2010;25 Suppl 2:S411–2.
   Google Scholar
• Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, Brotchie JM, Rees DD. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008;22:2488–97.
   PubMed Web of Science ®Google Scholar
• Johnston TH, Koprich JB, Fox SH, Howson PA, Brotchie JM. PYM50028 (Cogane) is a small molecule inducer of GDNF and BDNF that reverses behavioural impairment in MPTP-lesioned macaques. Parkinsonism Relat Disord. 2009;15 Suppl 2:S144.
   PubMedGoogle Scholar
• Phytopharm. Investigation of Cogane (PYM50028) in early-stage Parkinson's disease (CONFIDENT-PD) [Internet]. Bethesda (MD): US National Institutes of Health; 2010 [cited 2011 Nov 3]. Available from: http://clinicaltrials. gov/ct2/show/NCT01060878?term=PYM50028&rank=1
   Google Scholar
• Grégoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 2011;17(4):270–6.
   PubMed Web of Science ®Google Scholar
• Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Gasparini F, Johns D, Gomez-Mancilla B. A randomized, controlled trial evaluating AFQ056 in reducing L-dopa induced dyskinesia in patients with Parkinson's disease. Movement Disorder Society Meeting 2009, late breaking abstract LB05.
   Google Scholar
• Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Gasparini F, Hariry S, Vandemeulebroecke M, Johns D, Gomez-Mancilla B. AFQ056 treatment of severe levodopa-induced dyskinesias: proof of concept study. Mov Disord. 2010;25 Suppl 2:S290.
   Google Scholar
• Stocchi F, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Rascol O, Stacy M, Tolosa E, Trenkwalder C, Gao H, Nagel J, Gomez-Mancilla B, Merschhemke M, Tekin S, Abi-Saab W. A 13-week, double-blind, placebo-controlled study of AFQ056, a metabotropic glutamate receptor 5 antagonist in Parkinson's disease patients with moderate-to-severe L-dopa induced dyskinesia. Movement Disorder Society Meeting 2011, late breaking abstract LB12.
   Google Scholar
• Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord. 2003;18:872–83.
   PubMed Web of Science ®Google Scholar
• Dimitrova TD, Bara-Jimenez W, Savola J-M, Encarnacion E, Mouradian MM, Chase TN. Alpha-2 adrenergic antagonist effects in Parkinson's disease. Mov Disord. 2009;24 Suppl 1:S261.
   PubMedGoogle Scholar
• LeWitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, Leinonen M, Savola JM. Fipamezole in the treatment of dyskinesia in advanced Parkinson's disease (FJORD study). Mov Disord. 2010;25 Suppl 2:S300.
   PubMedGoogle Scholar
• Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson EM Jr, Milbrandt J. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature. 1996;384:467–70.
   PubMed Web of Science ®Google Scholar
• Herzog CD, Dass B, Holden JE, Stansell J 3rd, Gasmi M, Tuszynski MH, Bartus RT, Kordower JH. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord. 2007;22:1124–32.
   PubMed Web of Science ®Google Scholar
• Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J III, Gasmi M, Bartus RT. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006;60:706–15.
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008;7:400–8.
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9:1164–72.
   PubMed Web of Science ®Google Scholar
• Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, Johnson EM Jr, Olanow CW, Mufson EJ, Kordower JH. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011;26:27–36.
   PubMed Web of Science ®Google Scholar
• Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, During MJ. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science. 2002;298:425–9.
   PubMed Web of Science ®Google Scholar
• Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007;369:2097–105.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011;10(4):309–19.
   PubMed Web of Science ®Google Scholar